Breast Cancer

(Image: Getty/Shidlovski)

Genentech taps Halozyme’s tech in Herceptin Hylecta

By Maggie Lynch

Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.